Search - tctmd.com

Displaying 821 - 840 of 2269

Sort: Relevancy | Date

Presentation TCT 2019

COBRA REDUCE / MASTER DAPT

Presenter: Robert Byrne

September 27, 2019

Presentation TCT 2019

COMBO REDUCE

Presenter: Giuseppe De Luca

September 27, 2019

Presentation TCT 2019

XIENCE/ ONYX Short DAPT Programs

Presenter: Mitchell Krucoff

September 27, 2019

Presentation TCT 2019

Clinical Trial Design in HBR Patients: Should Risk Scores Be Incoporated?

Presenter: Davide Capodanno

September 27, 2019

Presentation TCT 2019

Idenifying the High Bleeding Risk Patient: The ARC HBR Definitions

Presenter: Philip Urban

September 27, 2019

Presentation TCT 2019

Case Presentation: A Patient at High Bleeding Risk and CAD- Real Management Dilemmas

Presenter: Davide Cao, MD

September 27, 2019

Presentation TCT 2019

Welcome and Introductions

Presenter: Roxana Mehran

September 27, 2019

Presentation TCT 2019

Study Design Considerations for HBR Patients in Japan

Presenter: Yasuko Nakamura

September 26, 2019

Presentation TCT 2019

Study Design Considerations for HBR Patients and DES Platforms: FDA View

Presenter: Adrian Magee

September 26, 2019

Presentation TCT 2019

PCI for HBD Patients in Japan: Current Clinical Treatment and Post-Market Treatment

Presenter: Junya Ako

September 26, 2019

Presentation TCT 2019

ARC Definition of High Bleeding Risk: Global Impact on HBR PCI Clinical Studies?

Presenter: Hans-Peter Stoll

September 26, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

Presentation TCT 2019

EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent

Presenter: Ajay Kirtane

September 26, 2019

Presentation TCT 2019

The Future in Managing Patients at High Bleeding Risk

Presenter: Elvin Kedhi

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

Presentation TCT 2019

Who is the High Bleeding Risk Patient?

Presenter: Daniel Simon

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

Presentation TCT 2019

Onyx ONE: A Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs. a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT

Presenter: Stephan Windecker

September 26, 2019

Advertisement

COBRA REDUCE / MASTER DAPT

COMBO REDUCE

XIENCE/ ONYX Short DAPT Programs

Clinical Trial Design in HBR Patients: Should Risk Scores Be Incoporated?

Idenifying the High Bleeding Risk Patient: The ARC HBR Definitions

Case Presentation: A Patient at High Bleeding Risk and CAD- Real Management Dilemmas

Welcome and Introductions

Study Design Considerations for HBR Patients in Japan

Study Design Considerations for HBR Patients and DES Platforms: FDA View

PCI for HBD Patients in Japan: Current Clinical Treatment and Post-Market Treatment

ARC Definition of High Bleeding Risk: Global Impact on HBR PCI Clinical Studies?

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent

The Future in Managing Patients at High Bleeding Risk

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

Who is the High Bleeding Risk Patient?

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Onyx ONE: A Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs. a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content